Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 6/2008

01-12-2008 | Original Article

Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy

Authors: Kunimitsu Kanai, Eiji Kikuchi, Takashi Ohigashi, Akira Miyajima, Ken Nakagawa, Jun Nakashima, Mototsugu Oya

Published in: International Journal of Clinical Oncology | Issue 6/2008

Login to get access
Metadata
Title
Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy
Authors
Kunimitsu Kanai
Eiji Kikuchi
Takashi Ohigashi
Akira Miyajima
Ken Nakagawa
Jun Nakashima
Mototsugu Oya
Publication date
01-12-2008
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2008
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-008-0779-x

Other articles of this Issue 6/2008

International Journal of Clinical Oncology 6/2008 Go to the issue

Case Report

Leptomeningeal metastasis from ovarian carcinoma successfully treated by the intraventricular administration of methotrexate

Case Report

Successful treatment of advanced gallbladder cancer with an anticancer drug S-1: assessment based on intratumoral gene

Original Article

Surgical complications of salvage total laryngectomy following concurrent chemoradiotherapy

Review Article

Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma

Case Report

Long-term complete response of multiple hepatic metastases from carcinoma of the papilla of Vater using intrahepatic infusion of 5-FU with low-dose cisplatin following pancreaticoduodenectomy

Case Report

Clear-cell adenocarcinoma of the uterine cervix in a 17-year-old adolescent
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits